New developments in the management of newly diagnosed metastatic prostate cancer

Abstract

The treatment algorithm for metastatic prostate cancer has changed more in the last decade than in the previous 50 years. Testosterone suppression has for many years been the gold standard for men newly diagnosed with prostate cancer. However, randomised studies have now shown that escalation of therapy beyond testosterone depletion results in profound and clinically meaningful survival benefits. This review aims to summarise the latest advancement in the field focusing on treatment of newly diagnosed hormone‐sensitive prostate cancer.